tirzepatide weight loss indianapolis GLP-1 | $300/mo Semaglutide and Tirzepatide Weight Loss
Description
Some plans deny coverage fully
This mental shortcut ignores the structural differences that matter
It is approved only for type 2 diabetes mellitus (Mounjaro) and chronic weight management (Zepbound), and any anti-inflammatory effects observed are considered secondary benefits
Its been estimated that 12% of Americans have used Mounjaro and similar GLP-1 agonists
Compounding for general weight loss, cost savings, or patient preference does not meet the legal criteria
